Sydney multicenter study of Parkinson's disease: Non-L-dopa–responsive problems dominate at 15 years
Corresponding Author
Mariese A. Hely MBBS
Department of Neurology, Westmead Hospital, Westmead New South Wales, Australia
Department of Neurology, Westmead Hospital, Westmead, NSW 2145, AustraliaSearch for more papers by this authorJohn G.L. Morris MD
Department of Neurology, Westmead Hospital, Westmead New South Wales, Australia
Search for more papers by this authorWayne G.J. Reid PhD
Department of Neurology, Westmead Hospital, Westmead New South Wales, Australia
Search for more papers by this authorRobert Trafficante BAppScMaths
Covance Pty Ltd, Ainslie, Australian Capital Territory, Australia
Search for more papers by this authorCorresponding Author
Mariese A. Hely MBBS
Department of Neurology, Westmead Hospital, Westmead New South Wales, Australia
Department of Neurology, Westmead Hospital, Westmead, NSW 2145, AustraliaSearch for more papers by this authorJohn G.L. Morris MD
Department of Neurology, Westmead Hospital, Westmead New South Wales, Australia
Search for more papers by this authorWayne G.J. Reid PhD
Department of Neurology, Westmead Hospital, Westmead New South Wales, Australia
Search for more papers by this authorRobert Trafficante BAppScMaths
Covance Pty Ltd, Ainslie, Australian Capital Territory, Australia
Search for more papers by this authorAbstract
One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicenter Study of Parkinson's disease have survived. The original study compared low-dose levodopa with low-dose bromocriptine. We now report the problems experienced by people who survive 15 years from diagnosis. The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms. Falls occur in 81% of patients, and 23% sustained fractures. Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression are experienced by 50%. Choking has occurred in 50%, symptomatic postural hypotension in 35%, and urinary incontinence in 41%. No patient is still employed, and 40% of patients live in aged care facilities. Although approximately 95% have experienced L-dopa–induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling. Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added. The rate of disease progression is similar in both arms of the study. We conclude that the most disabling long-term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L-dopa. Neuroprotective interventions in Parkinson's disease should be judged by their ability to improve non-L-dopa–responsive aspects of the disease, rather than just by their capacity to delay the introduction of L-dopa or reduce its associated side effects. © 2004 Movement Disorder Society
REFERENCES
- 1 Hely MA, Morris JGL, Trafficante R, Reid WGJ, O'Sullivan DJ, Williamson PM. The Sydney Multicentre Study of Parkinson's Disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999; 67: 300–307.
- 2 Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308–312.
- 3 Kuopio A-M, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov Disord 2000; 15: 216–223.
- 4 Di Rocco A. Molinari SP. Kollmeier B. Yahr MD. Parkinson's disease: progression and mortality in the L-DOPA era. Adv Neurol 1996; 69: 3–11.
- 5 Klawans HL. Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord 1986; 1: 187–192.
- 6 Hely MA, Morris JGL, Reid WDJ. The Sydney Multicentre Study of Parkinson's Disease: a randomised prospective 5 year study comparing low dose Bromocriptine with low dose Levodopa/Carbidopa. J. Neurol Neurosurg Psychiatry 1994; 57: 903–910.
- 7 Duvoisin RC. The evaluation of extrapyramidal disease. In: J de Ajuriguerra, G Gauthier, editors. Monoamines noyaux gris centraux et syndrome de Parkinson. Geneva: Georg and Cie; 1971. p 313–325.
- 8 Canter GJ, De la Torre R, Mier M. A method of evaluating disability in patients with Parkinson's disease J Nerv Ment Dis 1961; 133: 143–147.
- 9 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.
- 10 Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: S Fahn, CD Marsden, DB Calne, et al, editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ; MacMillan Healthcare information; 1987. p 153–163.
- 11 Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 17: 37–49.
- 12 Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
- 13 Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–572; updated by Morris J. The CDR: current version and scoring rules. Neurology 1993; 43: 2412–2413.
- 14 Reid WGJ, Hely MA, Morris JGL, et al. A longitudinal study of Parkinson's disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 1996; 3: 327–333.
- 15 World Health Organization. Manual of the international classification of diseases, injuries, and causes of death, 9th revision. Geneva: World Health Organization; 1978.
- 16 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184.
- 17 Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140–148.
- 18 Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995; 10: 250–256.
- 19 Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson's disease. Arch Neurol 1997; 54: 260–264.
- 20 Berger K, Breteler MMb, Helmer C, et al. Prognosis with Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2000; 54(Suppl. 5): S24–S27.
- 21 Lees AJ, Katzenschlager R, Head J, Ben-Schlomo Y. Ten-year follow-up of three different initial treatments in de-nove Parkinson's disease. A randomized trial. Neurology 2001; 57: 1687–1694.
- 22 Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995; 92: 55–58.
- 23 Curtis L, Lees AJ, Stern GM. Effect of L-dopa on course of Parkinson's disease. Lancet 1984; ii: 211–212.
- 24 Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993; 43: 1918–1926.
- 25 Poewe W. The Sydney Multicentre study of Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 290–299.
- 26 Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998; 43: 318–325.
- 27 Montastruc JL, Desboeuf K, Lapeyre-Mestre M, Senard J, Rascol O, Brefel-Courbon C. Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 2001; 16: 511–514.
- 28 Shill H. Stacy M. Respiratory function in Parkinson's disease. Clin Neurosci 1998; 5: 131–135.
- 29 Hely MA, Morris JGL, Lawrence S, Jeremy R, Genge SA. Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy [letter]. Aust N Z J Med 1991; 21: 82–84.
- 30 Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484–1491.
- 31 Hiner BC, Earnhart M. Ropinirole as compared with levodopa in Parkinson's disease. N Engl J Med 2000; 343: 884.
- 32 Senard JM, Raï S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 584–589.
- 33 Ørskov L, Jakobsen J, Dupont E, de Fine Olivarius B, Christensen NJ. Autonomic function in Parkinsonian patients relates to duration of disease. Neurology 1987; 37: 1173–1178.
- 34 Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992; 19: 508–519.
- 35 Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed Parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999; 67: 620–623.
- 36 Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T. SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopamine function in Parkinson's disease with urinary dysfunction. J Neurol Sci 2001; 187: 55–59.
- 37 Iqbal P, Castleden CM. Management of urinary incontinence in the elderly. Gerontology 1997; 43: 151–157.
- 38 Carter SE, Cambell EM, Sanson-Fisher RW, Gillespie WJ. Accidents in older people living at home: a community-based study assessing prevalence, type, location and injuries. Aust N Z J Public Health 2000; 24: 633–636.
- 39 Hely MA, Morris JGL, Reid WGJ, et al. Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand 1995; 92: 455–463.
- 40 Bonnet AM, Loria Y, Saint-Hilaire HM, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from non-dopaminergic lesions? Neurology 1987; 37: 1539–1542.
- 41 Tromp AM, Smit JH, Deeg DJ, Bouter LM, Lips P. Predictors of falls and fractures in the Longitudinal Aging study Amsterdam. J Bone Miner Res 1998; 13: 1932–1939.
- 42 Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349: 1793–1796.
- 43 Kumamoto T, Sannomiya K, Ueyama H, et al. Neurological abnormalities in cognitively impaired but not demented elderly. Acta Neurol Scand 2000; 102: 292–298.
- 44 Snowden J, Lane F. The prevalence and outcome of depression and dementia in Botany's elderly population. Int J Geriatr Psychiatry 2001; 16: 293–299.
- 45 Di Carlo A, Baldereschi M, Amaducci L, et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Geriatr Soc 2000; 48: 775–782.
- 46 Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson's disease. A community-based, prospective study. Neurology 2001; 56: 730–736.
- 47 Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson's disease. Arch Neurol 1996; 53: 538–542.
- 48 Martilla RJ, Rinne UK. Dementia in Parkinson's disease. Acta Neurol Scand 1976; 54: 431–441.
- 49 Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Aging 1999; 28: 39–43.
- 50 Martin WE Loewenson RB, Resch JA, Baker AB. Parkinson's disease. A clinical analysis of 100 patients. Neurology 1973; 23: 783–790.
- 51 Marder K, Leung D, Tang M, et al. Are demented patients with Parkinson's disease accurately reflected in prevalence surveys? A survival analysis. Neurology 1991; 41: 1240–1243.
- 52 Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 178–183.
- 53 Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54: 1596–1602.
- 54 Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord 1998; 13: 885–894.
- 55 Jellinger KA. Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm 1997; 51: S57–S82.
- 56 Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997; 49: 1570–1576.
- 57 Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149: 443–454.
- 58 Tandberg E, Larsen JP, Aasland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community based study. Arch Neurol 1996; 53: 175–179.
- 59 Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol Med 2001; 31: 65–73.
- 60 Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol 1995; 65: 61–84.
- 61 The Global Parkinson's Disease Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60–67.
- 62 Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000; 123: 733–745.
- 63 Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 734–738.
- 64 Aasland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 492–496.
- 65 Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669–671.
- 66 Goetz CG, Leurgans S, Pappert EJ, Ramen R, Stemer BA. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001; 57: 2078–2082.
- 67 Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391–403.